Clinical Trials
May 09, 2011

Dexamethasone Intravitreal Implant for Noninfectious Intermediate or Posterior Uveitis

Author Affiliations

Author Affiliations: Cole Eye Institute, Cleveland, Ohio (Dr Lowder); Vision Institute, Federal University of São Paulo, São Paulo, Brazil (Dr Belfort); Clinical Ophthalmology, Moorfields Eye Hospital, London, England (Dr Lightman); Massachusetts Eye Research and Surgery Institution and Ocular Immunology and Uveitis Foundation, Cambridge, Massachusetts (Dr Foster); and Allergan, Inc, Irvine, California (Drs Robinson, Schiffman, Li, Cui, and Whitcup).


Anne S.LindbladPhD


Copyright 2011 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.2011

Arch Ophthalmol. 2011;129(5):545-553. doi:10.1001/archophthalmol.2010.339

Uveitis refers to a group of intraocular inflammatory diseases that cause 10% to 15% of blindness in the developed world.14 Despite advances in immunosuppressive treatments, corticosteroids remain the mainstay of therapy.5,6 Many patients, however, are intolerant of or resistant to systemic steroids. Topical corticosteroids administered as eye drops are better tolerated than systemic corticosteroids but are typically only effective for anterior uveitis.5 Unfortunately, most of the severe vision loss related to uveitis occurs in patients with intermediate or posterior uveitis, in which the inflammation involves the vitreous and retina.5 Previously, these patients required systemic therapy, either with corticosteroids or other immunosuppressive agents, to control their ocular inflammation.5

First Page Preview View Large
First page PDF preview
First page PDF preview